A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

NCT ID: NCT05382325

Last Updated: 2024-11-14

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 70 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-16
• Study Completion Date: 2026-07-31

Brief Summary

The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.

Conditions

Advanced or Metastatic Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MK-1484

Participants will receive MK-1484 every 3 weeks (Q3W) or 21-day cycle at escalating dose levels from 0.2-60 mg for up to a total of 35 cycles (up to approximately 24 months).

Group Type: EXPERIMENTAL

MK-1484

Intervention Type: BIOLOGICAL

Subcutaneous (SC) injection

MK-1484 + Pembrolizumab

Participants will receive MK-1484 Q3W at escalating dose levels from 10-60 mg plus pembrolizumab 200 mg once every 21-day cycle for up to a total of 35 cycles (up to approximately 24 months).

Group Type: EXPERIMENTAL

MK-1484

Intervention Type: BIOLOGICAL

Subcutaneous (SC) injection

Pembrolizumab

Intervention Type: BIOLOGICAL

Intravenous (IV) infusion

Interventions

MK-1484

Subcutaneous (SC) injection

Intervention Type: BIOLOGICAL

Pembrolizumab

Intravenous (IV) infusion

Intervention Type: BIOLOGICAL

Other Intervention Names

SP'482; MK-3475; Keytruda®

Eligibility Criteria

Inclusion Criteria

• Has a histologically- or cytologically-confirmed advanced/metastatic solid tumor by pathology report and has received, or been intolerant to, all treatment known to confer clinical benefit.
• Has measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by the local site investigator/radiology.
• Has normal cardiac function based on transthoracic echocardiogram (TTE) or multigated acquisition scan (MUGA)
• Has provided an evaluable archival or newly obtained tumor tissue sample for biomarker analysis.
• Has adequate organ function.
• A male participant must agree to use contraception and should refrain from donating sperm during the specified period(s) of at least 120 days after study interventions.
• A female participant is eligible to participate if she is not pregnant or breastfeeding and at least 1 of the following: not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the treatment period for at least 120 days after study intervention.

Exclusion Criteria

• Has and chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before the first dose of study intervention, or has not recovered to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from any AEs that were due to cancer therapeutics administered more than 4 weeks earlier (this includes participants with previous immunomodulatory therapy with residual immune-related AEs). Participants receiving ongoing replacement hormone therapy for endocrine immune-related AEs will not be excluded from participation in this study.
• Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
• Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Has had a severe hypersensitivity reaction to treatment with a monoclonal antibody and/or components of the study interventions.
• Has an active infection requiring therapy.
• Has a history of interstitial lung disease.
• Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.
• Has an active autoimmune disease that has required systemic treatment in the past 2 years except vitiligo or resolved childhood asthma/atopy.
• Participants with known human immunodeficiency virus (HIV) and/or hepatitis B or C infections, or known to be positive for hepatitis B surface antigen (HBsAg)/hepatitis B virus (HBV) DNA or hepatitis C Antibody or ribonucleic acid (RNA).
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, make administration of the study drugs hazardous, or make it difficult to monitor adverse effects such that it is not in the best interest of the participant to participate.
• Has known psychiatric or substance abuse disorders that would interfere with the participant's ability to cooperate with the requirements of the study.
• Has not fully recovered from any effects of major surgery without significant detectable infection. Surgeries that required general anesthesia must be completed at least 2 weeks before first study intervention administration. Surgery requiring regional/epidural anesthesia must be completed at least 72 hours before first study intervention administration and participants should be recovered.
• Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before the start of study treatment.
• Has had an allogeneic tissue/solid organ transplant in the last 5 years or has evidence of graft-versus-host disease.
• Has received any prior interleukin-2 (IL-2) based therapy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Sanford Cancer Center ( Site 0005)

Sioux Falls, South Dakota, United States

NEXT Oncology ( Site 0001)

San Antonio, Texas, United States

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011)

Toronto, Ontario, Canada

Rambam Health Care Campus-Oncology ( Site 0021)

Haifa, , Israel

Sheba Medical Center-ONCOLOGY ( Site 0020)

Ramat Gan, , Israel

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0035)

Amsterdam, North Holland, Netherlands

Erasmus Medisch Centrum-Medical Oncology ( Site 0036)

Rotterdam, South Holland, Netherlands

Universitair Medisch Centrum Utrecht-Medical Oncology ( Site 0037)

Utrecht, , Netherlands

Countries

United States; Canada; Israel; Netherlands

Related Links

https://www.merckclinicaltrials.com/

Merck Clinical Trials Information

https://msd.trialsummaries.com/Study/StudyDetails?id=26211&tenant=MT_MSD_9011

Plain Language Summary

Other Identifiers

MK-1484-001

Identifier Type: OTHER

Identifier Source: secondary_id

2023-505067-36

Identifier Type: REGISTRY

Identifier Source: secondary_id

2021-005220-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1484-001

Identifier Type: -

Identifier Source: org_study_id